L. Devizzi
University of Milan
19 Papers
84 Citations
L. Devizzi is an academic researcher from University of Milan. The author has contributed to research in topics: Medicine & Rituximab. The author has an hindex of 10, co-authored 18 publications.
Chat about Author
Papers
Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group
Gail Ryan,Giovanni Martinelli,M. Kuper-Hommel,Richard W. Tsang,Giancarlo Pruneri,Ka Y Yuen,Daniel E. Roos,Anne Lennard,L. Devizzi,Simon J. Crabb,Dieter K. Hossfeld,Guy Pratt,M Dell'Olio,S P Choo,Robert G. Bociek,John Radford,Stephen Lade,Alessandro M. Gianni,Emanuele Zucca,Franco Cavalli,John F. Seymour +20 more
TL;DR: The combination of limited surgery, anthracycline-containing chemotherapy, and involved-field RT produced the best outcome in the pre-rituximab era, and a prospective trial is pursued to confirm these results.
257
Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion
Michele Magni,M. Di Nicola,L. Devizzi,Paola Matteucci,F. Lombardi,Lorenza Gandola,Fernando Ravagnani,Roberto Giardini,G Dastoli,Corrado Tarella,Alessandro Pileri,G. Bonadonna,Alessandro M. Gianni +12 more
TL;DR: An in vivo purging method capable of providing tumor-free stem cell products from most patients with mantle cell or follicular lymphoma and bone marrow involvement is developed, suggesting the presence of a more-than-additive antilymphoma effect of the chemoimmunotherapy combination used.
227
Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi)
Corrado Tarella,Manuela Zanni,M Di Nicola,C. Patti,R Calvi,Alessandra Pescarollo,Valerio Zoli,Alessandro Fornari,Domenico Novero,Antonello Cabras,M Stella,A Comino,D. Remotti,Maurilio Ponzoni,Daniele Caracciolo,M Ladetto,Michele Magni,L. Devizzi,Rosalba Rosato,Mario Boccadoro,M. Bregni,Paolo Corradini,Andrea Gallamini,Ignazio Majolino,S. Mirto,A.M. Gianni +25 more
TL;DR: Life expectancy of younger patients with diffuse large B-cell lymphoma and age-adjusted International Prognostic Score 2-3 DLB-CL is improved with the early administration of rituximab-supplemented intensive chemotherapy compared with the poor outcome following conventional chemotherapy.
76
Ifosfamide and vinorelbine: an active regimen for patients with relapsed or refractory Hodgkin's disease.
V. Bonfante,S. Viviani,Antonella Santoro,L. Devizzi,A. Di Russo,M. Zanini,F. Soncini,H. Soto Parra,P. Valagussa,G. Bonadonna +9 more
TL;DR: Twenty‐six patients with relapsed or refractory Hodgkin's disease were treated with an intensive salvage regimen combining ifosfamide and vinorelbine with mesna uroprotection and G‐CSF support.
44
Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma
Anna Dodero,Anna Guidetti,Alessandra Tucci,Francesco Barretta,M. Novo,L. Devizzi,Alessandro Re,Angela Passi,Alessio Pellegrinelli,Giancarlo Pruneri,Rosalba Miceli,Adele Testi,Martina Pennisi,M. C. Di Chio,Paola Matteucci,C. Carniti,Fabio Facchetti,Giorgio Rossi,Paolo Corradini +18 more
TL;DR: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alphaketoglutarate to 2-hydroxyglutarate, which accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations.